Arcutis Biotherapeutics, Inc.
For the period ended Sep 30, 2026. Filed Nov 4, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 4, 2026
ARQT$27.39+4.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)
(In thousands, except per share data)
| Three Months EndedSeptember 30, | Nine Months Ended September 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| Revenues: | ||||
| Product revenue, net | $143,919 | $99,219 | $379,178 | $244,569 |
| Other revenue | — | — | — | 2,000 |
| Total revenues | 143,919 | 99,219 | 379,178 | 246,569 |
| Operating expenses: | ||||
| Cost of sales | 12,460 | 8,685 | 33,183 | 25,007 |
| Research and development | 22,422 | 19,604 | 73,404 | 56,600 |
| Selling, general and administrative | 99,601 | 62,404 | 255,815 | 195,576 |
| Total operating expenses | 134,483 | 90,693 | 362,402 | 277,183 |
| Income (loss) from operations | 9,436 | 8,526 | 16,776 | (30,614) |
| Other income (expense): | ||||
| Interest income | 2,596 | 2,118 | 7,150 | 6,731 |
| Interest expense | (2,959) | (3,071) | (10,733) | (9,082) |
| Other income (expense), net | (77) | (83) | (254) | 130 |
| Total other income (expense) | (440) | (1,036) | (3,837) | (2,221) |
| Income (loss) before income taxes | 8,996 | 7,490 | 12,939 | (32,835) |
| Provision for income taxes | 195 | 80 | 424 | 701 |
| Net income (loss) | $8,801 | $7,410 | $12,515 | $(33,536) |
| Other comprehensive income (loss): | ||||
| Unrealized gain (loss) on marketable securities | (498) | 68 | (945) | (164) |
| Foreign currency translation adjustment | (15) | (95) | (180) | 109 |
| Total other comprehensive income (loss) | (513) | (27) | (1,125) | (55) |
| Comprehensive income (loss) | $8,288 | $7,383 | $11,390 | $(33,591) |
| Earnings (loss) per share: | ||||
| Basic | $0.07 | $0.06 | $0.10 | $(0.26) |
| Diluted | $0.06 | $0.06 | $0.09 | $(0.26) |
| Weighted-average shares used in computing earnings (loss) per share: | ||||
| Basic | 131,011 | 127,623 | 130,306 | 126,891 |
| Diluted | 136,836 | 132,885 | 136,192 | 126,891 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.